Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.
J Am Coll Cardiol. 2010 Oct 19;56(17):1357-65. doi: 10.1016/j.jacc.2010.07.016.
Intense investigation continues on the pathobiology of stent thrombosis (ST) because of its morbidity and mortality. Because little advance has been made in outcomes following ST, ongoing research is focused on further understanding predictive factors as well as ST frequency and timing in various patient subsets, depending upon whether a drug-eluting stent or bare-metal stent has been implanted. Although the preventive role of antiplatelet therapies remains unchallenged, new data on genomics and variability in response to antiplatelet therapy, as well as the effects of novel therapeutic agents and duration of therapy, have become available. The goal remains identification of patients at particularly increased risk of ST so that optimal prevention strategies can be developed and employed.
由于支架血栓形成 (ST) 的发病率和死亡率，对其发病机制的深入研究仍在继续。由于 ST 后的结果几乎没有进展，因此正在进行的研究侧重于进一步了解预测因素以及不同患者亚组的 ST 频率和时间，具体取决于植入的是药物洗脱支架还是裸金属支架。尽管抗血小板治疗的预防作用仍然没有受到挑战，但关于基因组学和对血小板治疗反应的变异性的新数据，以及新型治疗药物的作用和治疗持续时间，已经出现。目标仍然是确定那些 ST 风险特别高的患者，以便制定和采用最佳的预防策略。
